Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10338457rdf:typepubmed:Citationlld:pubmed
pubmed-article:10338457lifeskim:mentionsumls-concept:C1457887lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0018801lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0023977lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0242606lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0025859lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0054836lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0015259lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C2700378lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:10338457lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:10338457pubmed:issue20lld:pubmed
pubmed-article:10338457pubmed:dateCreated1999-6-15lld:pubmed
pubmed-article:10338457pubmed:abstractTextWith beta-blocker use becoming more prevalent in treating chronic heart failure (CHF), the choice of drugs raises important theoretical and practical questions. Although the second-generation compound metoprolol is beta1-selective, the third-generation compound carvedilol is beta-nonselective, with ancillary pharmacological properties including alpha-blockade and antioxidant effects. A prospective comparison of these 2 agents can address the issue of optimal adrenergic blockade in selecting agents for therapy in CHF.lld:pubmed
pubmed-article:10338457pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:languageenglld:pubmed
pubmed-article:10338457pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:citationSubsetAIMlld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10338457pubmed:statusMEDLINElld:pubmed
pubmed-article:10338457pubmed:monthMaylld:pubmed
pubmed-article:10338457pubmed:issn1524-4539lld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:FOXRRlld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:KalmanJJlld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:CharneyR HRHlld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:KukinM LMLlld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:LevyD KDKlld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:Buchholz-Varl...lld:pubmed
pubmed-article:10338457pubmed:authorpubmed-author:OcampoO NONlld:pubmed
pubmed-article:10338457pubmed:issnTypeElectroniclld:pubmed
pubmed-article:10338457pubmed:day25lld:pubmed
pubmed-article:10338457pubmed:volume99lld:pubmed
pubmed-article:10338457pubmed:ownerNLMlld:pubmed
pubmed-article:10338457pubmed:authorsCompleteYlld:pubmed
pubmed-article:10338457pubmed:pagination2645-51lld:pubmed
pubmed-article:10338457pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:meshHeadingpubmed-meshheading:10338457...lld:pubmed
pubmed-article:10338457pubmed:year1999lld:pubmed
pubmed-article:10338457pubmed:articleTitleProspective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure.lld:pubmed
pubmed-article:10338457pubmed:affiliationCardiovascular Institute, Mount Sinai School of Medicine, New York, NY 10029, USA. marrickvkukin@mssm.edulld:pubmed
pubmed-article:10338457pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10338457pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:10338457pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:10338457pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:10338457pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10338457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10338457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10338457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10338457lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10338457lld:pubmed